<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607112452001</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607112452001</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Clinical Guidelines</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A.S.P.E.N. Clinical Guidelines</article-title>
<subtitle>Nutrition Support of Adult Patients With Hyperglycemia</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>McMahon</surname><given-names>M. Molly</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607112452001">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nystrom</surname><given-names>Erin</given-names></name>
<degrees>PharmD, BCNSP</degrees>
<xref ref-type="aff" rid="aff2-0148607112452001">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Braunschweig</surname><given-names>Carol</given-names></name>
<degrees>PhD, RD</degrees>
<xref ref-type="aff" rid="aff3-0148607112452001">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Miles</surname><given-names>John</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0148607112452001">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Compher</surname><given-names>Charlene</given-names></name>
<degrees>PhD, RD, CNSC, LDN, FADA</degrees>
<xref ref-type="aff" rid="aff4-0148607112452001">4</xref>
</contrib>
<contrib contrib-type="author">
<collab>the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors</collab>
</contrib>
</contrib-group>
<aff id="aff1-0148607112452001"><label>1</label>Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota</aff>
<aff id="aff2-0148607112452001"><label>2</label>Nutrition Support, Mayo Clinic, Rochester, Minnesota</aff>
<aff id="aff3-0148607112452001"><label>3</label>Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, Illinois</aff>
<aff id="aff4-0148607112452001"><label>4</label>University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania</aff>
<author-notes>
<corresp id="corresp1-0148607112452001">Charlene Compher, PhD, RD, CNSC, LDN, FADA, Associate Professor of Nutrition Science, University of Pennsylvania School of Nursing, Claire M. Fagin Hall, 418 Curie Boulevard, Philadelphia, PA 19104-4217, USA. Email: <email>compherc@nursing.upenn.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>37</volume>
<issue>1</issue>
<fpage>23</fpage>
<lpage>36</lpage>
<history>
<date date-type="received">
<day>25</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: Hyperglycemia is a frequent occurrence in adult hospitalized patients who receive nutrition support. Both hyperglycemia and hypoglycemia (resulting from attempts to correct hyperglycemia) are associated with adverse outcomes in diabetic as well as nondiabetic patients. This American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Clinical Guideline summarizes the most current evidence and provides guidelines for the desired blood glucose goal range in hospitalized patients receiving nutrition support, the definition of hypoglycemia, and the rationale for use of diabetes-specific enteral formulas in hospitalized patients. <italic>Method</italic>: A systematic review of the best available evidence to answer a series of questions regarding glucose control in adults receiving parenteral or enteral nutrition was undertaken and evaluated using concepts adopted from the Grading of Recommendations, Assessment, Development and Evaluation working group. A consensus process was used to develop the clinical guideline recommendations prior to external and internal review and approval by the A.S.P.E.N. Board of Directors. <italic>Results/Conclusions</italic>: 1. What is the desired blood glucose goal range in adult hospitalized patients receiving nutrition support? We recommend a target blood glucose goal range of 140–180 mg/dL (7.8–10 mmol/L). (Strong) 2. How is hypoglycemia defined in adult hospitalized patients receiving nutrition support? We recommend that hypoglycemia be defined as a blood glucose concentration of &lt;70 mg/dL (&lt;3.9 mmol/L). (Strong) 3. Should diabetes-specific enteral formulas be used for adult hospitalized patients with hyperglycemia? We cannot make a recommendation at this time.</p>
</abstract>
<kwd-group>
<kwd>hyperglycemia</kwd>
<kwd>endocrinology</kwd>
<kwd>diabetes</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607112452001">
<title>Background</title>
<p>Hyperglycemia is a frequent occurrence in hospitalized patients who receive nutrition support. A survey of 126 U.S. hospitals found that the prevalence of hyperglycemia (blood glucose &gt;180 mg/dL [10 mmol/L]) was 46% in the intensive care unit (ICU) and 32% in non-ICU areas.<sup><xref ref-type="bibr" rid="bibr1-0148607112452001">1</xref></sup> Both hyperglycemia and hypoglycemia are associated with adverse outcomes in patients with diabetes mellitus as well as nondiabetic patients.<sup><xref ref-type="bibr" rid="bibr1-0148607112452001">1</xref>,<xref ref-type="bibr" rid="bibr2-0148607112452001">2</xref></sup> Numerous trials have been conducted to investigate whether tight control of blood glucose affects outcomes, and the results have been inconsistent. Differences among studies may relate in part to timing of initiating nutrition, route of nutrition administration, caloric provision, glycemic target, and methods of blood glucose testing. This American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Clinical Guideline summarizes the most current evidence and provides guidelines for the desired blood glucose goal range in hospitalized patients receiving nutrition support, the definition of hypoglycemia, and the rationale for use of diabetes-specific enteral formulas in hospitalized patients. This guideline does not address other specific strategies for managing hyperglycemia in patients receiving nutrition support, as there are little to no data to support clinical practice recommendations in this area.</p>
</sec>
<sec id="section2-0148607112452001" sec-type="methods">
<title>Methodology</title>
<p>The American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) is an organization composed of healthcare professionals representing the disciplines of medicine, nursing, pharmacy, dietetics, and nutrition science. The mission of A.S.P.E.N. is to improve patient care by advancing the science and practice of clinical nutrition and metabolism. A.S.P.E.N. vigorously works to support quality patient care, education, and research in the fields of nutrition and metabolic support in all healthcare settings. These Clinical Guidelines were developed under the guidance of the A.S.P.E.N. Board of Directors. Promotion of safe and effective patient care by nutrition support practitioners is a critical role of the A.S.P.E.N. organization. The A.S.P.E.N. Board of Directors has been publishing Clinical Guidelines since 1986.<sup><xref ref-type="bibr" rid="bibr3-0148607112452001">3</xref><xref ref-type="bibr" rid="bibr4-0148607112452001"/><xref ref-type="bibr" rid="bibr5-0148607112452001"/><xref ref-type="bibr" rid="bibr6-0148607112452001"/><xref ref-type="bibr" rid="bibr7-0148607112452001"/><xref ref-type="bibr" rid="bibr8-0148607112452001"/><xref ref-type="bibr" rid="bibr9-0148607112452001"/><xref ref-type="bibr" rid="bibr10-0148607112452001"/><xref ref-type="bibr" rid="bibr11-0148607112452001"/><xref ref-type="bibr" rid="bibr12-0148607112452001"/><xref ref-type="bibr" rid="bibr13-0148607112452001"/>-<xref ref-type="bibr" rid="bibr14-0148607112452001">14</xref></sup> A.S.P.E.N. evaluates in an ongoing process when individual Clinical Guidelines should be updated.</p>
<p>These A.S.P.E.N. Clinical Guidelines are based on general conclusions of health professionals who, in developing such guidelines, have balanced potential benefits to be derived from a particular mode of medical therapy against certain risks inherent with such therapy. However, the professional judgment of the attending health professional is the primary component of quality medical care. Because guidelines cannot account for every variation in circumstances, the practitioner must always exercise professional judgment in their application. These Clinical Guidelines are intended to supplement, but not replace, professional training and judgment.</p>
<p>A.S.P.E.N. Clinical Guidelines have adopted concepts of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) working group.<sup><xref ref-type="bibr" rid="bibr15-0148607112452001">15</xref><xref ref-type="bibr" rid="bibr16-0148607112452001"/>-<xref ref-type="bibr" rid="bibr17-0148607112452001">17</xref></sup> A full description of the methodology has been published.<sup><xref ref-type="bibr" rid="bibr18-0148607112452001">18</xref></sup> Briefly, specific clinical questions where nutrition support is a relevant mode of therapy are developed and key clinical outcomes are identified. A rigorous search of the published literature is conducted, each included study assessed for research quality, tables of findings developed, the body of evidence for the question evaluated, and a recommendation for clinical practice that is based on both the best available evidence and the risks and benefits to patients developed by consensus. Recommendations are graded as strong when the evidence is strong and/or net benefits outweigh harms. Weak recommendations may be based on weaker evidence and/or important trade-offs to the patient. When limited research is available to answer a question, no recommendation can be made.</p>
</sec>
<sec id="section3-0148607112452001" sec-type="results">
<title>Results</title>
<p>For the current Clinical Guideline, inclusion criteria of adult subjects, complication of hyperglycemia, and hospital setting were used. The questions are summarized in <xref ref-type="table" rid="table1-0148607112452001">Table 1</xref>. Search terms of <italic>diabetes mellitus, hyperglycemia, hypoglycemia, clinical outcomes, parenteral nutrition</italic>, and <italic>enteral nutrition</italic> were applied in various combinations to CENTRAL (The Cochrane Library), MEDLINE, EMBASE, Science Citation Index Expanded, LILACS, and CINAHL (until December 2011).</p>
<table-wrap id="table1-0148607112452001" position="float">
<label>Table 1.</label>
<caption>
<p>Nutrition Support Clinical Guideline Recommendations in Adult Hospitalized Patients With Hyperglycemia.</p>
</caption>
<graphic alternate-form-of="table1-0148607112452001" xlink:href="10.1177_0148607112452001-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Question</th>
<th align="center">Recommendation</th>
<th align="center">Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>What is the desired blood glucose goal range in adult hospitalized patients receiving nutrition support?</td>
<td>We recommend a target blood glucose goal range of 140–180 mg/dL (7.8–10 mmol/L).</td>
<td>Strong</td>
</tr>
<tr>
<td>How is hypoglycemia defined in adult hospitalized patients receiving nutrition support?</td>
<td>We recommend that hypoglycemia be defined as a blood concentration of &lt;70 mg/dL (&lt;3.9 mmol/L).</td>
<td>Strong</td>
</tr>
<tr>
<td>Should diabetes-specific enteral formulas be used for adult hospitalized patients with hyperglycemia?</td>
<td>We cannot make a recommendation at this time.</td>
<td>Further research needed</td>
</tr>
</tbody>
</table>
</table-wrap>
<list id="list1-0148607112452001" list-type="simple">
<list-item><p><bold>Question 1</bold>. What is the desired blood glucose goal range in adult hospitalized patients receiving nutrition support (<xref ref-type="table" rid="table2-0148607112452001">Tables 2</xref> and <xref ref-type="table" rid="table3-0148607112452001">3</xref>)?</p></list-item>
<list-item><p><bold>Recommendation:</bold> We recommend a target blood glucose goal range of 140–180 mg/dL (7.8–10 mmol/L).</p></list-item>
<list-item><p><bold>Grade:</bold> Strong</p></list-item>
<list-item><p><bold>Rationale:</bold> Hyperglycemia is associated with increased mortality in hospitalized patients, both in the ICU<sup><xref ref-type="bibr" rid="bibr19-0148607112452001">19</xref></sup> and the non-ICU setting.<sup><xref ref-type="bibr" rid="bibr20-0148607112452001">20</xref></sup> No clinical trials have been specifically designed to determine the effect of different blood glucose targets in adult hospitalized patients receiving nutrition support on clinical outcomes.</p></list-item>
</list>
<table-wrap id="table2-0148607112452001" position="float">
<label>Table 2.</label>
<caption>
<p>Evidence Table Question 1: What Is the Desired Glucose Goal Range in Adult Hospitalized Patients Receiving Nutrition Support?</p>
</caption>
<graphic alternate-form-of="table2-0148607112452001" xlink:href="10.1177_0148607112452001-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Author (ref #)</th>
<th align="center">Study Design, Quality</th>
<th align="center">Population, Setting, N</th>
<th align="center">Study Objective</th>
<th align="center">Primary End Points</th>
<th align="center">Results</th>
<th align="center">Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Van den Berghe, 2001<sup><xref ref-type="bibr" rid="bibr21-0148607112452001">21</xref></sup></td>
<td>RCT, unblinded, single center</td>
<td>Surgical ICU patients (N = 1548)</td>
<td>Compared tight glycemic control (target ≤110 mg/dL; 6.1 mmol/L) to less stringent control (180–200 mg/dL; 10–11.1 mmol/L)</td>
<td>In-hospital mortality</td>
<td>34% reduction in in-hospital mortality with tight glycemic control (<italic>P</italic> &lt; .04)</td>
<td>Used blood gas machine, which has superior accuracy and precision to other point-of-care devices, for glucose measurements; majority received PN and may have been overfed</td>
</tr>
<tr>
<td>Furnary, 2003<sup><xref ref-type="bibr" rid="bibr22-0148607112452001">22</xref></sup></td>
<td>Historical controls, single center</td>
<td>Post-CABG (N = 3554)</td>
<td>Compared tight glycemic control (variable target) to less stringent control (&lt;200 mg/dL; 11.1 mmol/L)</td>
<td>In-hospital mortality</td>
<td>53% reduction in in-hospital mortality with tight glycemic control (<italic>P</italic> = .002)</td>
<td>Few patients received nutrition support; point-of-care glucose measurements</td>
</tr>
<tr>
<td>Krinsley, 2004<sup><xref ref-type="bibr" rid="bibr23-0148607112452001">23</xref></sup></td>
<td>Historical controls, single center</td>
<td>Medical-surgical ICU (N = 1600)</td>
<td>Compared tight glycemic control (target ≤140 mg/dL; 7.8 mmol/L) to less stringent control (“usual care”)</td>
<td>In-hospital mortality</td>
<td>29% reduction in in-hospital mortality with tight glycemic control (<italic>P</italic> = .002)</td>
<td>Mode of feeding was almost entirely enteral; point-of-care glucose measurements</td>
</tr>
<tr>
<td>Cheung, 2005<sup><xref ref-type="bibr" rid="bibr24-0148607112452001">24</xref></sup></td>
<td>Retrospective chart review</td>
<td>Hospitalized patients fed with PN (N = 109)</td>
<td>Evaluated association of hyperglycemia during PN on clinical outcomes</td>
<td>In-hospital mortality; cardiac, renal, infectious outcomes while fed with PN</td>
<td>Hyperglycemia of &gt;164 mg/dL (9.1 mmol/L) in patients receiving PN was associated with increased mortality compared with those with blood glucose &lt;124 mg/dL (6.9 mmol/L) (OR, 10.9; 95% CI, 2.0–60.5; <italic>P</italic> &lt; .01); blood glucose of &gt;142 mg/dL fed with PN was associated with increased risk of all complications</td>
<td>Retrospective design</td>
</tr>
<tr>
<td>Van den Berghe, 2006<sup><xref ref-type="bibr" rid="bibr25-0148607112452001">25</xref></sup></td>
<td>RCT, unblinded, single center</td>
<td>Medical ICU patients (N = 1200)</td>
<td>Compared tight glycemic control (target ≤110 mg/dL; 6.1 mmol/L) to less stringent control (180–200 mg/dL; 10–11.1 mmol/L)</td>
<td>In-hospital mortality</td>
<td>No difference in mortality between groups treated with intensive vs conventional insulin</td>
<td>Patients fed via parenteral and enteral routes; arterial glucose sampling and point-of-care devices for glucose analysis</td>
</tr>
<tr>
<td>Lin, 2007<sup><xref ref-type="bibr" rid="bibr26-0148607112452001">26</xref></sup></td>
<td>Retrospective chart review</td>
<td>Hospitalized patients fed with PN (N = 457)</td>
<td>Evaluated the association between hyperglycemia and outcomes in patients fed with PN</td>
<td>In-hospital mortality</td>
<td>Mortality risk increased significantly with increasing degree of hyperglycemia during PN use compared with patients with glucose &lt;114 mg/dL (6.3 mmol/L)</td>
<td>Retrospective design</td>
</tr>
<tr>
<td>Brunkhorst, 2008<sup><xref ref-type="bibr" rid="bibr27-0148607112452001">27</xref></sup></td>
<td>RCT, 2-by-2 factorial design, unblinded, multicenter</td>
<td>Medical-surgical ICU patients with severe sepsis or septic shock (N = 537)</td>
<td>Compared tight glycemic control (target ≤110 mg/dL; 6.1 mmol/L) to less stringent control (180–200 mg/dL; 10.0–11.1 mmol/L)</td>
<td>28-day mortality and morbidity (mean SOFA)</td>
<td>No difference in mortality and mean SOFA scores were similar between groups treated with intensive vs conventional insulin</td>
<td>Intensive insulin therapy arm terminated early due to high frequency of hypoglycemia; mode of feeding was shared between enteral and parenteral routes; point-of-care or arterial glucose measurements</td>
</tr>
<tr>
<td>De La Rosa, 2008<sup><xref ref-type="bibr" rid="bibr28-0148607112452001">28</xref></sup></td>
<td>RCT, unblinded, single center</td>
<td>Medical-surgical ICU (N = 504)</td>
<td>Compared tight glycemic control (target ≤110 mg/dL; 6.1 mmol/L) to less stringent control (180–200 mg/dL; 10–11.1 mmol/L)</td>
<td>28-day mortality</td>
<td>No difference in mortality between groups treated with intensive vs conventional insulin</td>
<td>Majority of patients received EN; arterial glucose sampling and point-of-care devices for glucose analysis</td>
</tr>
<tr>
<td>Arabi, 2008<sup><xref ref-type="bibr" rid="bibr29-0148607112452001">29</xref></sup></td>
<td>RCT, unblinded, single center</td>
<td>Medical-surgical ICU (N = 523)</td>
<td>Compared tight glycemic control (target ≤110 mg/dL; 6.1 mmol/L) to less stringent control (180–200 mg/dL; 10–11.1 mmol/L)</td>
<td>ICU mortality</td>
<td>No difference in mortality between groups treated with intensive vs conventional insulin</td>
<td>Majority of patients received EN; arterial glucose sampling and point-of-care devices for glucose analysis</td>
</tr>
<tr>
<td>Preiser, 2009<sup><xref ref-type="bibr" rid="bibr30-0148607112452001">30</xref></sup></td>
<td>RCT, unblinded, multicenter</td>
<td>Medical-surgical ICU patients (N = 1078)</td>
<td>Compared tight glycemic control (target ≤110 mg/dL; 6.1 mmol/L) to less stringent control (140–180 mg/dL; 7.8–10.0 mmol/L)</td>
<td>ICU mortality</td>
<td>No difference in mortality between patients treated with intensive vs conventional insulin</td>
<td>Study was terminated early due to protocol violations and therefore was underpowered; majority received EN and were not overfed; arterial or central venous glucose sampling or point-of-care glucose measurements</td>
</tr>
<tr>
<td>NICE-SUGAR, 2009<sup><xref ref-type="bibr" rid="bibr31-0148607112452001">31</xref></sup></td>
<td>RCT, unblinded, multicenter</td>
<td>Medical-surgical ICU patients (N = 6104)</td>
<td>Compared tight glycemic control (target ≤108 mg/dL; 6.0 mmol/L) to less stringent control (140–180 mg/dL; 7.8–10.0 mmol/L)</td>
<td>90-day all-cause mortality</td>
<td>Mortality was 10.1% higher in the intensive insulin arm of the study (<italic>P</italic> = .02)</td>
<td>Majority received EN and were not overfed; used both blood gas analysis and point-of-care devices for glucose analysis</td>
</tr>
<tr>
<td>Pasquel, 2010<sup><xref ref-type="bibr" rid="bibr2-0148607112452001">2</xref></sup></td>
<td>Retrospective chart review</td>
<td>Hospitalized patients fed with PN (N = 276)</td>
<td>Evaluated clinical predictive capability of the glycemic response to PN</td>
<td>Hospital length of stay, hospital complications, mortality</td>
<td>Blood glucose within 24 hours of PN initiation of &gt;180 mg/dL (10 mmol/L) was associated with increased mortality (OR, 2.8; 95% CI, 1.2–6.8; <italic>P</italic> = .020) and increased risk of pneumonia (OR, 3.1; 95% CI, 1.4–7.1) and acute renal failure (OR, 2.3; 95% CI, 1.1–5.0)</td>
<td>Retrospective design</td>
</tr>
<tr>
<td>Sarkisian, 2010<sup><xref ref-type="bibr" rid="bibr32-0148607112452001">32</xref></sup></td>
<td>Retrospective chart review</td>
<td>Non–critically ill inpatients fed with PN (N = 100)</td>
<td>Determined the association of PN use with hyperglycemia (&gt;180 mg/dL; 10.0 mmol/L) and the association of hyperglycemia on healthcare outcomes</td>
<td>Acute coronary events, renal failure, infection, hospital length of stay, ICU admission, sepsis, and mortality</td>
<td>Hyperglycemia in patients receiving PN was associated with increased mortality (OR, 7.22; 95% CI, 1.08–48.29; <italic>P</italic> = .042)</td>
<td>Retrospective design; small study population (only 17/100 patients had hyperglycemia)</td>
</tr>
<tr>
<td>Lee, 2011<sup><xref ref-type="bibr" rid="bibr33-0148607112452001">33</xref></sup></td>
<td>Retrospective chart review</td>
<td>Medical ICU, fed with PN without history of diabetes mellitus (N = 88)</td>
<td>Determined effect of PN dextrose provision on hyperglycemia (≥140 mg/dL; 7.8 mmol/L) and clinical outcomes</td>
<td>Relationship between hyperglycemia and complications (infectious, renal, cardiac) and mortality</td>
<td>Patients who were hyperglycemic received more dextrose from PN; hyperglycemia was associated with increased mortality compared to patients fed with PN with normoglycemia (42.4% vs 12.8%, <italic>P</italic> = .008)</td>
<td>Retrospective design, small study population</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607112452001">
<p>CABG, coronary artery bypass graft; CI, confidence interval; EN, enteral nutrition; ICU, intensive care unit; NICE-SUGAR, Normoglycemia in Intensive Care Evaluation Survival Using Glucose Algorithm Regulation; OR, odds ratio; PN, parenteral nutrition; RCT, randomized controlled trial; SOFA, Sequential Organ Failure Assessment; VISEP, Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-0148607112452001" position="float">
<label>Table 3.</label>
<caption>
<p>GRADE Table Question 1: What Is the Desired Glucose Goal Range in Adult Hospitalized Patients Receiving Nutrition Support?</p>
</caption>
<graphic alternate-form-of="table3-0148607112452001" xlink:href="10.1177_0148607112452001-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Comparison</th>
<th align="center">Outcome</th>
<th align="center">Quantity, Type Evidence</th>
<th align="center">Findings</th>
<th align="center">GRADE of Evidence for Outcome</th>
<th align="center">Overall Recommendation GRADE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tight vs standard glucose control</td>
<td>Mortality</td>
<td>7 RCTs,<sup><xref ref-type="bibr" rid="bibr21-0148607112452001">21</xref>,<xref ref-type="bibr" rid="bibr25-0148607112452001">25</xref>,<xref ref-type="bibr" rid="bibr27-0148607112452001">27</xref><xref ref-type="bibr" rid="bibr28-0148607112452001"/><xref ref-type="bibr" rid="bibr29-0148607112452001"/><xref ref-type="bibr" rid="bibr30-0148607112452001"/>-<xref ref-type="bibr" rid="bibr31-0148607112452001">31</xref></sup> 2 historical control trials,<sup><xref ref-type="bibr" rid="bibr22-0148607112452001">22</xref>,<xref ref-type="bibr" rid="bibr23-0148607112452001">23</xref></sup> 5 retrospective reviews<sup><xref ref-type="bibr" rid="bibr2-0148607112452001">2</xref>,<xref ref-type="bibr" rid="bibr24-0148607112452001">24</xref>,<xref ref-type="bibr" rid="bibr26-0148607112452001">26</xref>,<xref ref-type="bibr" rid="bibr32-0148607112452001">32</xref>,<xref ref-type="bibr" rid="bibr33-0148607112452001">33</xref></sup></td>
<td>Tight glycemic control was better in 1 RCT<sup><xref ref-type="bibr" rid="bibr21-0148607112452001">21</xref></sup> and 2 historical control trials,<sup><xref ref-type="bibr" rid="bibr22-0148607112452001">22</xref>,<xref ref-type="bibr" rid="bibr23-0148607112452001">23</xref></sup> no different in 5 RCTs,<sup><xref ref-type="bibr" rid="bibr25-0148607112452001">25</xref>,<xref ref-type="bibr" rid="bibr27-0148607112452001">27</xref><xref ref-type="bibr" rid="bibr28-0148607112452001"/><xref ref-type="bibr" rid="bibr29-0148607112452001"/>-<xref ref-type="bibr" rid="bibr30-0148607112452001">30</xref></sup> and worse in the largest RCT<sup><xref ref-type="bibr" rid="bibr31-0148607112452001">31</xref></sup>; 5 retrospective reviews suggest harm with PN-associated hyperglycemia<sup><xref ref-type="bibr" rid="bibr2-0148607112452001">2</xref>,<xref ref-type="bibr" rid="bibr24-0148607112452001">24</xref>,<xref ref-type="bibr" rid="bibr26-0148607112452001">26</xref>,<xref ref-type="bibr" rid="bibr32-0148607112452001">32</xref>,<xref ref-type="bibr" rid="bibr33-0148607112452001">33</xref></sup></td>
<td>Moderate</td>
<td>Strong</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0148607112452001">
<p>PN, parenteral nutrition; RCT, randomized controlled trial.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Earlier studies<sup><xref ref-type="bibr" rid="bibr21-0148607112452001">21</xref><xref ref-type="bibr" rid="bibr22-0148607112452001"/>-<xref ref-type="bibr" rid="bibr23-0148607112452001">23</xref></sup> showed that management of hyperglycemia with an insulin infusion in the ICU was associated with a reduction in mortality, leading a consensus conference to recommend that blood glucose concentrations in hospitalized patients be maintained below 110 mg/dL (6.1 mmol/L).<sup><xref ref-type="bibr" rid="bibr34-0148607112452001">34</xref></sup> However, more recent large clinical trials failed to show benefit when such an aggressive target was achieved.<sup><xref ref-type="bibr" rid="bibr25-0148607112452001">25</xref>,<xref ref-type="bibr" rid="bibr27-0148607112452001">27</xref><xref ref-type="bibr" rid="bibr28-0148607112452001"/><xref ref-type="bibr" rid="bibr29-0148607112452001"/><xref ref-type="bibr" rid="bibr30-0148607112452001"/>-<xref ref-type="bibr" rid="bibr31-0148607112452001">31</xref>,<xref ref-type="bibr" rid="bibr35-0148607112452001">35</xref></sup> The largest randomized controlled trial that used primarily enteral nutrition at levels of energy intake that were appropriate actually found a higher mortality in patients treated with intensive treatment compared with those treated to a target blood glucose range of 140–180 mg/dL (7.8–10 mmol/L).<sup><xref ref-type="bibr" rid="bibr31-0148607112452001">31</xref></sup> The explanation for these disparate results is not entirely clear, but hypoglycemia associated with aggressive treatment in the more recent studies is one likely explanation. It is apparent that mild to moderate hypoglycemia (40–70 mg/dL; 2.2–3.9 mmol/L) is not innocuous but rather is associated with adverse outcomes. No trials have compared a broader target glycemic range with a lower limit, for example, 110–180 mg/dL (6.1–10.0 mmol/L), to intensive treatment. Because of these findings, we recommend that the target blood glucose concentration in the critically ill adult should be 140–180 mg/dL (7.8–10 mmol/L). No randomized controlled trials have been conducted in non-ICU patients. This recommendation is consistent with those of the American Association of Clinical Endocrinologists, the American Diabetes Association,<sup><xref ref-type="bibr" rid="bibr36-0148607112452001">36</xref></sup> and the Endocrine Society.<sup><xref ref-type="bibr" rid="bibr37-0148607112452001">37</xref></sup></p>
<list id="list2-0148607112452001" list-type="simple">
<list-item><p><bold>Question 2</bold>. How is hypoglycemia defined in adult hospitalized patients receiving nutrition support (<xref ref-type="table" rid="table4-0148607112452001">Tables 4</xref> and <xref ref-type="table" rid="table5-0148607112452001">5</xref>)?</p></list-item>
<list-item><p><bold>Recommendation:</bold> We recommend that hypoglycemia be defined as a blood glucose concentration of &lt;70 mg/dL (&lt;3.9 mmol/L).</p></list-item>
<list-item><p><bold>Grade:</bold> Strong</p></list-item>
<list-item><p><bold>Rationale:</bold> Hypoglycemia is associated with adverse outcomes in hospitalized patients.<sup><xref ref-type="bibr" rid="bibr25-0148607112452001">25</xref>,<xref ref-type="bibr" rid="bibr38-0148607112452001">38</xref>,<xref ref-type="bibr" rid="bibr39-0148607112452001">39</xref>,<xref ref-type="bibr" rid="bibr40-0148607112452001">40</xref><xref ref-type="bibr" rid="bibr41-0148607112452001"/><xref ref-type="bibr" rid="bibr42-0148607112452001"/><xref ref-type="bibr" rid="bibr43-0148607112452001"/><xref ref-type="bibr" rid="bibr44-0148607112452001"/><xref ref-type="bibr" rid="bibr45-0148607112452001"/><xref ref-type="bibr" rid="bibr46-0148607112452001"/><xref ref-type="bibr" rid="bibr47-0148607112452001"/><xref ref-type="bibr" rid="bibr48-0148607112452001"/><xref ref-type="bibr" rid="bibr49-0148607112452001"/><xref ref-type="bibr" rid="bibr50-0148607112452001"/><xref ref-type="bibr" rid="bibr51-0148607112452001"/><xref ref-type="bibr" rid="bibr52-0148607112452001"/><xref ref-type="bibr" rid="bibr53-0148607112452001"/>-<xref ref-type="bibr" rid="bibr54-0148607112452001">54</xref></sup> Hypoglycemia could be partly responsible for the adverse effects noted with intensive insulin therapy, including mortality.<sup><xref ref-type="bibr" rid="bibr25-0148607112452001">25</xref></sup> A large retrospective analysis of hypoglycemia in ICUs showed a stepwise and significant increase in mortality with increasingly severe hypoglycemia.<sup><xref ref-type="bibr" rid="bibr38-0148607112452001">38</xref></sup> This recommendation carries a strong recommendation grade based on our assessment of the significant risk to the patient of hypoglycemia in the context of tight glucose control.</p></list-item>
</list>
<table-wrap id="table4-0148607112452001" position="float">
<label>Table 4.</label>
<caption>
<p>Evidence Table Question 2: How Is Hypoglycemia Defined in Adult Hospitalized Patients Receiving Nutrition Support?</p>
</caption>
<graphic alternate-form-of="table4-0148607112452001" xlink:href="10.1177_0148607112452001-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Author (ref #)</th>
<th align="center">Study Design, Quality</th>
<th align="center">Population, Setting, N</th>
<th align="center">Study Objective</th>
<th align="center">Primary End Points</th>
<th align="center">Results</th>
<th align="center">Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boucai, 2011<sup><xref ref-type="bibr" rid="bibr40-0148607112452001">40</xref></sup></td>
<td>Retrospective record review</td>
<td>Hospitalized patients, not in ICU, with at least 1 blood glucose &lt;70 mg/dL (3.9 mmol/L), N = 3349 of 31,970 total admissions</td>
<td>Evaluate mortality risk associated with hypoglycemia</td>
<td>Mortality</td>
<td>Hypoglycemia (HR, 1.67; 95% CI, 1.33–2.09; <italic>P</italic> &lt; 0.001)</td>
<td>Hypoglycemia may be a marker of disease rather than a direct cause of death</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>In patients with spontaneous hypoglycemia (HR, 2.72; 95% CI, 1.97–3.47; <italic>P</italic> &lt; .001)</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>After adjustment for comorbidities, relationship no longer significant</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>In patients with insulin-induced hypoglycemia (HR, 1.06; 95% CI, 0.74–1.52)</td>
<td/>
</tr>
<tr>
<td>Chi, 2011<sup><xref ref-type="bibr" rid="bibr41-0148607112452001">41</xref></sup></td>
<td>Retrospective record review</td>
<td>Consecutive admissions to shock/trauma ICU, N = 3125</td>
<td>Examine the impact of glycemic states on mortality; hypoglycemia as blood glucose ≤60 mg/dL</td>
<td>Mortality</td>
<td>Hypoglycemia increased actual risk beyond predicted and in dose-response fashion</td>
<td/>
</tr>
<tr>
<td>D’Ancona 2011<sup><xref ref-type="bibr" rid="bibr42-0148607112452001">42</xref></sup></td>
<td>Retrospective record review</td>
<td>Consecutive cardiac surgery patients, N = 596</td>
<td>Examine impact of hyperglycemia (blood glucose &gt;180 mg/dL) and hypoglycemia (blood glucose &lt;70 mg/dL (3.9 mmol/L) on clinical outcomes</td>
<td>Mortality</td>
<td>Hypoglycemia (OR, 20.0; 95% CI, 2.9–136.9; <italic>P</italic> = .002)</td>
<td/>
</tr>
<tr>
<td>Hermanides, 2010<sup><xref ref-type="bibr" rid="bibr43-0148607112452001">43</xref></sup></td>
<td>Retrospective record review</td>
<td>Medical ICU, N = 2168 Cardiothoracic surgical ICU, N = 3560</td>
<td>Evaluate impact of blood glucose variability vs mortality; hypoglycemia as blood glucose ≤45 mg/dL</td>
<td>Mortality</td>
<td>High glucose variability may be more important than hypoglycemia alone in predicting mortality</td>
<td/>
</tr>
<tr>
<td>Krinsley, 2011<sup><xref ref-type="bibr" rid="bibr44-0148607112452001">44</xref></sup></td>
<td>Retrospective record review</td>
<td>ICU patients from 6 hospitals, N = 6240</td>
<td>Assess mortality risk of blood glucose &lt;70 mg/dL (3.9 mmol/L)</td>
<td>Mortality</td>
<td>Glucose &lt;70 mg/dL (3.9 mmol/L); (RR, 1.78; 95% CI, 1.39–2.27, <italic>P</italic> &lt; .0001)</td>
<td>Dose-response relationship with mortality risk vs level of hypoglycemia</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Glucose 40–69 mg/dL; (RR, 1.29; 95% CI, 1.11–1.51, <italic>P</italic> = .0011)</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Glucose &lt;40 mg/dL; (RR, 1.87; 95% CI, 1.46–2.40, <italic>P</italic> &lt; .0001)</td>
<td/>
</tr>
<tr>
<td>Mortensen, 2010<sup><xref ref-type="bibr" rid="bibr45-0148607112452001">45</xref></sup></td>
<td>Retrospective record review</td>
<td>Patients admitted with pneumonia; hypoglycemia as blood glucose &lt;70 mg/dL (3.9 mmol/L), N = 787</td>
<td>Examine whether hypoglycemia as &lt;70 mg/dL (3.9 mmol/L) is associated with increased 30-day mortality, after adjusting for potential confounders</td>
<td>Mortality</td>
<td>Hypoglycemia (adjusted OR, 4.1; 95% CI, 1.4–11.7)</td>
<td/>
</tr>
<tr>
<td>Siegelaar, 2010<sup><xref ref-type="bibr" rid="bibr46-0148607112452001">46</xref></sup></td>
<td>Retrospective record review</td>
<td>Medical, surgical ICU patients, N = 5828</td>
<td>Examine impact of intensive insulin therapy to achieve glycemic target of 70–125 mg/dL (4–7 mmol/L)</td>
<td>Mortality</td>
<td>Mean glucose ≤6.6 mmol/L (OR, 2.4; 95% CI, 1.4–4, <italic>P</italic> = .002) in medical patients</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Mean glucose ≤6.9 mmol/L (OR, 4.9; 95% CI, 1.2–21.6, <italic>P</italic> = .03) in surgical patients</td>
<td/>
</tr>
<tr>
<td>Stamou, 2011<sup><xref ref-type="bibr" rid="bibr47-0148607112452001">47</xref></sup></td>
<td>Retrospective record review</td>
<td>Consecutive cardiac surgery patients, N = 2538</td>
<td>Identify risk factors for hypoglycemia during intensive insulin therapy</td>
<td>Hypoglycemia as blood glucose &lt;60 mg/dL (3.3 mmol/L)</td>
<td>Hypoglycemia independent predictor (OR, 2.7; 95% CI, 1.1–6.3, <italic>P</italic> = .027)</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td>Examine their impact on surgical mortality</td>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Durao, 2010<sup><xref ref-type="bibr" rid="bibr48-0148607112452001">48</xref></sup></td>
<td>Retrospective record review</td>
<td>ICU admissions assigned to target blood glucose 4.4–6.1 mmol/L vs 4.4–8 mmol/L, N = 130</td>
<td>Evaluate mortality associated with 2 glucose control regimens</td>
<td>Mortality</td>
<td>Hypoglycemia (OR, 2.9; 95% CI, 1.21–7.41)</td>
<td>Small sample, randomization not mentioned</td>
</tr>
<tr>
<td/>
<td/>
<td>Hypoglycemia as blood glucose &lt;3.3 mmol/L</td>
<td/>
<td/>
<td/>
<td/>
</tr>
<tr>
<td>Egi, 2010<sup><xref ref-type="bibr" rid="bibr38-0148607112452001">38</xref></sup></td>
<td>Retrospective record review</td>
<td>Patients admitted to ICU who also had hypoglycemia, N = 1109</td>
<td>Evaluate impact of mild (glucose 72–81 mg/dL) or moderate (glucose &lt;71 mg/dL) hypoglycemia on mortality</td>
<td>Mortality</td>
<td>Both hospital and ICU mortality OR increased dose-dependently with lower levels of hypoglycemia</td>
<td/>
</tr>
<tr>
<td>Arabi, 2009<sup><xref ref-type="bibr" rid="bibr49-0148607112452001">49</xref></sup></td>
<td>Retrospective record review of nested cohort within RCT</td>
<td>Medical-surgical ICU patients, N = 523</td>
<td>Determine predicting factors for hypoglycemia as blood glucose ≤40 mg/dL (2.2 mmol/L); assess impact on mortality</td>
<td>ICU mortality</td>
<td>Adjusted for confounders, hypoglycemia not significantly associated with increased mortality (HR, 1.31; 95% CI, 0.7–2.46)</td>
<td>Relatively small sample size, no power analysis</td>
</tr>
<tr>
<td>Kosiborod, 2009<sup><xref ref-type="bibr" rid="bibr50-0148607112452001">50</xref></sup></td>
<td>Retrospective record review</td>
<td>Patients hospitalized with acute MI and hyperglycemia, N = 7820</td>
<td>Determine whether mortality risk associated with hypoglycemia is similar in patients who develop hypoglycemia spontaneously and those who develop it as a result of insulin therapy</td>
<td>Mortality</td>
<td>Hypoglycemia in patients who were not treated with insulin vs normoglycemic patients (OR, 2.32; 95% CI, 1.31–4.12)</td>
<td>Authors attribute hypoglycemia risk to more severe critical illness, not to insulin</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>No difference in hypoglycemia treated with insulin vs normoglycemic patients (OR, 0.92; 95% CI, 0.58–1.45)</td>
<td/>
</tr>
<tr>
<td>Turchin, 2009<sup><xref ref-type="bibr" rid="bibr51-0148607112452001">51</xref></sup></td>
<td>Retrospective record review</td>
<td>Patients with diabetes admitted to non-ICU area, N = 4368 admissions of 2582 patients</td>
<td>Determine whether hypoglycemic episodes as blood glucose ≤50 mg/dL (2.8 mmol/L) are associated with higher mortality in diabetic patients hospitalized in the general ward</td>
<td>Inpatient and 1-year mortality</td>
<td>Odds of inpatient death rose 3-fold for every 10-mg/dL decrease in the lowest blood glucose during hospitalization (<italic>P</italic> = .0058)</td>
<td>Patients treated with PN excluded from analysis</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Mortality at 1 year not impacted</td>
<td/>
</tr>
<tr>
<td>Bagshaw, 2009<sup><xref ref-type="bibr" rid="bibr52-0148607112452001">52</xref></sup></td>
<td>Retrospective record review</td>
<td>Consecutive admissions to ICU, N = 66,184</td>
<td>Examine impact of early hypoglycemia as blood glucose &lt;80 mg/dL (4.5 mmol/L)</td>
<td>Mortality</td>
<td>Hypoglycemia vs ICU mortality (OR, 1.41; 95% CI, 1.31–1.54)</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Hypoglycemia vs hospital mortality (OR, 1.36; 95% CI, 1.27–1.46)</td>
<td/>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Mortality higher with lower levels of hypoglycemia</td>
<td/>
</tr>
<tr>
<td>Kaukonen, 2009<sup><xref ref-type="bibr" rid="bibr53-0148607112452001">53</xref></sup></td>
<td>Retrospective record review</td>
<td>Consecutive admissions to ICU, N = 1124</td>
<td>Examine incidence of hypoglycemia as blood glucose &lt;72 mg/dL (4 mmol/L) and impact on mortality</td>
<td>Mortality</td>
<td>Hypoglycemia vs no hypoglycemia, 24% vs 14.7%, <italic>P</italic> = .11</td>
<td>Small sample size (n = 25 patients with hypoglycemia) limits power</td>
</tr>
<tr>
<td>Krinsley, 2007<sup><xref ref-type="bibr" rid="bibr54-0148607112452001">54</xref></sup></td>
<td>Retrospective record review with case control</td>
<td>Consecutive patients admitted to medical, surgical, or cardiac ICU, N = 5372; patients with severe hypoglycemia, N = 102</td>
<td>Determine risk factors for development of severe hypoglycemia defined as glucose &lt;40 mg/dL (2.2 mmol/L) in critically ill patients and define the outcomes of this complication</td>
<td>Mortality</td>
<td>Severe hypoglycemia independent predictor of mortality (OR, 2.28; 95% CI, 1.41–3.70; <italic>P</italic> = .0008)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0148607112452001">
<p>CI, confidence interval; HR, hazard ratio; ICU, intensive care unit; MI, myocardial infarction; OR, odds ratio; PN, parenteral nutrition; RCT, randomized controlled trial; RR, relative risk.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0148607112452001" position="float">
<label>Table 5.</label>
<caption>
<p>GRADE Table Question 2: What Glucose Range Should Define Hypoglycemia?</p>
</caption>
<graphic alternate-form-of="table5-0148607112452001" xlink:href="10.1177_0148607112452001-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Comparison</th>
<th align="center">Outcome</th>
<th align="center">Quantity, Type Evidence</th>
<th align="center">Findings</th>
<th align="center">GRADE of Evidence for Outcome</th>
<th align="center">Overall Recommendation GRADE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normoglycemia vs hypoglycemia</td>
<td>Mortality</td>
<td>16 OBS<sup><xref ref-type="bibr" rid="bibr38-0148607112452001">38</xref>,<xref ref-type="bibr" rid="bibr40-0148607112452001">40</xref><xref ref-type="bibr" rid="bibr41-0148607112452001"/><xref ref-type="bibr" rid="bibr42-0148607112452001"/><xref ref-type="bibr" rid="bibr43-0148607112452001"/><xref ref-type="bibr" rid="bibr44-0148607112452001"/><xref ref-type="bibr" rid="bibr45-0148607112452001"/><xref ref-type="bibr" rid="bibr46-0148607112452001"/><xref ref-type="bibr" rid="bibr47-0148607112452001"/><xref ref-type="bibr" rid="bibr48-0148607112452001"/><xref ref-type="bibr" rid="bibr49-0148607112452001"/><xref ref-type="bibr" rid="bibr50-0148607112452001"/><xref ref-type="bibr" rid="bibr51-0148607112452001"/><xref ref-type="bibr" rid="bibr52-0148607112452001"/><xref ref-type="bibr" rid="bibr53-0148607112452001"/>-<xref ref-type="bibr" rid="bibr54-0148607112452001">54</xref></sup></td>
<td>14 Increased risk,<sup><xref ref-type="bibr" rid="bibr40-0148607112452001">40</xref><xref ref-type="bibr" rid="bibr41-0148607112452001"/><xref ref-type="bibr" rid="bibr42-0148607112452001"/><xref ref-type="bibr" rid="bibr43-0148607112452001"/><xref ref-type="bibr" rid="bibr44-0148607112452001"/><xref ref-type="bibr" rid="bibr45-0148607112452001"/><xref ref-type="bibr" rid="bibr46-0148607112452001"/><xref ref-type="bibr" rid="bibr47-0148607112452001"/>-<xref ref-type="bibr" rid="bibr48-0148607112452001">48</xref>,<xref ref-type="bibr" rid="bibr50-0148607112452001">50</xref>,<xref ref-type="bibr" rid="bibr52-0148607112452001">52</xref>,<xref ref-type="bibr" rid="bibr54-0148607112452001">54</xref></sup> 2 no difference<sup><xref ref-type="bibr" rid="bibr49-0148607112452001">49</xref>,<xref ref-type="bibr" rid="bibr53-0148607112452001">53</xref></sup></td>
<td>Low</td>
<td>Strong</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0148607112452001">
<p>OBS, observational study.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Symptoms of hypoglycemia can be missed in hospitalized patients who are sedated or ventilated, or with impaired sensorium. The American Diabetes Association Workgroup on Hypoglycemia and the American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control define hypoglycemia as any blood glucose &lt;70 mg/dL (&lt;3.9 mmol/L).<sup><xref ref-type="bibr" rid="bibr36-0148607112452001">36</xref></sup> This value is the accepted definition in ambulatory patients and is a level at which counterregulatory hormone release (including sympathoadrenal activation) occurs. It is reasonable to apply the definition of hypoglycemia in ambulatory patients to hospitalized patients. Antecedent hypoglycemia of this level can reduce the secretion of counterregulatory hormones resulting in impaired responsiveness to subsequent hypoglycemia.<sup><xref ref-type="bibr" rid="bibr55-0148607112452001">55</xref><xref ref-type="bibr" rid="bibr56-0148607112452001"/>-<xref ref-type="bibr" rid="bibr57-0148607112452001">57</xref></sup> While some studies have defined hypoglycemia in critically ill patients as &lt;40 mg/dL (&lt;2.2 mmol/L), that threshold is lower than the level at which cognitive impairment can occur and is therefore not safe. In addition, a variety of point-of-care testing methods for blood glucose are used in hospitalized patients. The accuracy and precision of blood glucose monitoring devices is relatively poor, especially at low glucose concentrations.<sup><xref ref-type="bibr" rid="bibr14-0148607112452001">14</xref>,<xref ref-type="bibr" rid="bibr58-0148607112452001">58</xref></sup> Using a blood glucose threshold of 70 mg/dL (3.9 mmol/L) instead of a lower value offers the additional benefit of a safety buffer to accommodate such testing errors. Regardless of the definition threshold of hypoglycemia, patients with symptoms of hypoglycemia at a higher level than 70 mg/dL (3.9 mmol/L) may require treatment for symptoms of hypoglycemia.</p>
<list id="list3-0148607112452001" list-type="simple">
<list-item><p><bold>Question 3</bold>. Should diabetes-specific enteral formulas be used for hospitalized patients with hyperglycemia (<xref ref-type="table" rid="table6-0148607112452001">Tables 6</xref> and <xref ref-type="table" rid="table7-0148607112452001">7</xref>)?</p></list-item>
<list-item><p><bold>Recommendation:</bold> We cannot make a recommendation at this time.</p></list-item>
<list-item><p><bold>Grade:</bold> Further research needed</p></list-item>
<list-item><p><bold>Rationale:</bold> The availability of enteral formulas with lower carbohydrate and higher monounsaturated fat content (compared with standard formulas commonly used in clinical settings) and with or without added fiber has prompted studies examining the effects on glycemic control. Additionally, most trials are short-term or single-meal studies, use oral nutrition supplements, or were conducted in long-term care facilities, rehabilitation, or other outpatient settings, limiting their application to hospitalized patients requiring enteral nutrition.</p></list-item>
</list>
<table-wrap id="table6-0148607112452001" position="float">
<label>Table 6.</label>
<caption>
<p>Evidence Table Question 3: Should Diabetes-Specific Enteral Formulas Be Used for Adult Hospitalized Patients With Hyperglycemia?</p>
</caption>
<graphic alternate-form-of="table6-0148607112452001" xlink:href="10.1177_0148607112452001-table6.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Author (ref #)</th>
<th align="center">Study Design, Quality</th>
<th align="center">Population, Setting, N</th>
<th align="center">Study Objective</th>
<th align="center">Primary End Points</th>
<th align="center">Results</th>
<th align="center">Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leon-Sanz, 2005<sup><xref ref-type="bibr" rid="bibr59-0148607112452001">59</xref></sup></td>
<td>RCT, unblinded</td>
<td>Hospitalized with head/neck cancer or neurologic disorder and with type 2 diabetes mellitus (N = 104)</td>
<td>Compared 2 diabetes-specific formulas (high CHO from starch and sucrose vs low CHO/high MUFA)</td>
<td>Blood glucose level, triglyceride level, daily insulin requirement</td>
<td>No significant difference in glucose, triglycerides, or insulin requirements</td>
<td>No standard enteral formula comparison; analysis conducted only in patients who fulfilled energy intake goal and completed 2 weeks of treatment (32 of 104 patients randomized)</td>
</tr>
<tr>
<td>Mesejo, 2003<sup><xref ref-type="bibr" rid="bibr60-0148607112452001">60</xref></sup></td>
<td>RCT, single blinded</td>
<td>Intensive care unit; stress hyperglycemia or diabetes mellitus type 1 or 2 (N = 50)</td>
<td>Compared high protein/high MUFA + fiber vs high protein control EN</td>
<td>Glycemic control, insulin requirement</td>
<td>Significant improvement in glycemic control: 176.8 ± 44.0 vs 222.8 ± 47.1 mg/dL (<italic>P</italic> = .001)</td>
<td>Included patients with and without diabetes mellitus</td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td/>
<td>Significant improvement in median insulin requirement at 14 days: 8.7 (2.3–27.5) vs 30.2 (21.5–51.7) U/d (<italic>P</italic> = .001)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0148607112452001">
<p>CHO, carbohydrate; EN, enteral nutrition; MUFA, mono-unsaturated fatty acid; RCT, randomized controlled trial.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table7-0148607112452001" position="float">
<label>Table 7.</label>
<caption>
<p>GRADE Table Question 3: Should Diabetes-Specific Enteral Formulas Be Used for Adult Hospitalized Patients With Hyperglycemia?</p>
</caption>
<graphic alternate-form-of="table7-0148607112452001" xlink:href="10.1177_0148607112452001-table7.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Comparison</th>
<th align="center">Outcome</th>
<th align="center">Quantity, Type Evidence</th>
<th align="center">Findings</th>
<th align="center">GRADE of Evidence for Outcome</th>
<th align="center">Overall Recommendation GRADE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes formula vs standard</td>
<td>Glycemic control</td>
<td>2 RCTs<sup><xref ref-type="bibr" rid="bibr59-0148607112452001">59</xref>,<xref ref-type="bibr" rid="bibr60-0148607112452001">60</xref></sup></td>
<td>1 No difference,<sup><xref ref-type="bibr" rid="bibr59-0148607112452001">59</xref></sup> 1 improved<sup><xref ref-type="bibr" rid="bibr60-0148607112452001">60</xref></sup></td>
<td>Low</td>
<td>Further research needed</td>
</tr>
<tr>
<td/>
<td>Insulin requirement</td>
<td>2 RCTs<sup><xref ref-type="bibr" rid="bibr59-0148607112452001">59</xref>,<xref ref-type="bibr" rid="bibr60-0148607112452001">60</xref></sup></td>
<td>1 No difference,<sup><xref ref-type="bibr" rid="bibr59-0148607112452001">59</xref></sup> 1 improved<sup><xref ref-type="bibr" rid="bibr60-0148607112452001">60</xref></sup></td>
<td>Low</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0148607112452001">
<p>RCT, randomized controlled trial.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The trials that evaluated disease-specific formulas in patients requiring long-term nutrition support used glycemic or lipid control as their primary outcomes, as they were not sufficiently powered to detect differences in morbidity and/or mortality.<sup><xref ref-type="bibr" rid="bibr59-0148607112452001">59</xref>,<xref ref-type="bibr" rid="bibr60-0148607112452001">60</xref></sup> The impact on glycemic and lipid control was inconclusive. Additional research is required.</p>
</sec>
</body>
<back>
<ack>
<p><italic>A.S.P.E.N. Board of Directors Providing Final Approval</italic></p>
<p>Jay Mirtallo, MS, RPh, BCNSP, FASHP; Tom Jaksic, MD, PhD; Ainsley Malone, MS, RD, CNSC; Lawrence A. Robinson, BS, MS, PharmD; Charles W. Van Way III, MD, FASPEN; Phil Ayers, PharmD, BCNSP; Praveen S. Goday, MBBS, CNSC; Carol Ireton-Jones, PhD, RD, LD, CNSD; Elizabeth M. Lyman, MSN, RN; and Daniel Teitelbaum, MD.</p>
<p><italic>A.S.P.E.N. Clinical Guidelines Editorial Board</italic></p>
<p>Charlene Compher, PhD, RD, CNSC, LDN, FADA; Joseph I. Boullata, PharmD, RPh, BCNSP; Carol L. Braunschweig, PhD, RD; Mary Ellen Druyan, PhD, MPH, RD, CNS, FACN; Donald E. George, MD; Edwin Simpser, MD; and Patricia A. Worthington, MSN, RN, CNSN.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607112452001">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cook</surname><given-names>CB</given-names></name>
<name><surname>Kongable</surname><given-names>GL</given-names></name>
<name><surname>Potter</surname><given-names>DJ</given-names></name>
<name><surname>Abad</surname><given-names>VJ</given-names></name>
<name><surname>Leija</surname><given-names>DE</given-names></name>
<name><surname>Anderson</surname><given-names>M</given-names></name>
</person-group>. <article-title>Inpatient glucose control: a glycemic survey of 126 U.S. hospitals</article-title>. <source>J Hosp Med</source>. <year>2009</year>;<volume>4</volume>:<fpage>E7</fpage>-<lpage>E14</lpage>.</citation>
</ref>
<ref id="bibr2-0148607112452001">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pasquel</surname><given-names>FJ</given-names></name>
<name><surname>Spiegelman</surname><given-names>R</given-names></name>
<name><surname>McCauley</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Hyperglycemia during total parenteral nutrition: an important marker of poor outcome and mortality in hospitalized patients</article-title>. <source>Diabetes Care</source>. <year>2010</year>;<volume>33</volume>(<issue>4</issue>):<fpage>739</fpage>-<lpage>741</lpage>.</citation>
</ref>
<ref id="bibr3-0148607112452001">
<label>3.</label>
<citation citation-type="journal">
<collab>A.S.P.E.N</collab>. <article-title>Board of Directors. Guidelines for use of total parenteral nutrition in the hospitalized adult patient</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1986</year>;<volume>10</volume>(<issue>5</issue>):<fpage>441</fpage>-<lpage>445</lpage>.</citation>
</ref>
<ref id="bibr4-0148607112452001">
<label>4.</label>
<citation citation-type="journal">
<collab>A.S.P.E.N</collab>. <article-title>Board of Directors. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1993</year>;<volume>17</volume>(<supplement>suppl 4</supplement>):<fpage>1SA</fpage>-<lpage>52SA</lpage>.</citation>
</ref>
<ref id="bibr5-0148607112452001">
<label>5.</label>
<citation citation-type="journal">
<collab>A.S.P.E.N</collab>. <article-title>Board of Directors. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients</article-title> [published correction appears in <italic>JPEN J Parenter Enteral Nutr</italic>. 2002;26:114]. <source>JPEN J Parenter Enteral Nutr</source>. <year>2002</year>;<volume>26</volume>:<fpage>1SA</fpage>-<lpage>138SA</lpage>.</citation>
</ref>
<ref id="bibr6-0148607112452001">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehta</surname><given-names>NM</given-names></name>
<name><surname>Compher</surname><given-names>C</given-names></name>
</person-group>; <collab>American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors</collab>. <article-title>A.S.P.E.N. clinical guidelines: nutrition support of the critically ill child</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>: <fpage>260</fpage>-<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr7-0148607112452001">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McClave</surname><given-names>SA</given-names></name>
<name><surname>Martindale</surname><given-names>RG</given-names></name>
<name><surname>Vanek</surname><given-names>VW</given-names></name>
<etal/>
</person-group>.; <collab>A.S.P.E.N. Board of Directors; American College of Critical Care Medicine</collab>. <article-title>Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>:<fpage>277</fpage>-<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr8-0148607112452001">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>August</surname><given-names>DA</given-names></name>
<name><surname>Huhmann</surname><given-names>MB</given-names></name>
</person-group>; <collab>American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors</collab>. <article-title>A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>(<issue>5</issue>):<fpage>472</fpage>-<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr9-0148607112452001">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sabery</surname><given-names>N</given-names></name>
<name><surname>Duggan</surname><given-names>C</given-names></name>
</person-group>; <collab>American Society for Parenteral and Enteral Nutrition Board of Directors</collab>. <article-title>A.S.P.E.N. clinical guidelines: nutrition support of children with human immunodeficiency virus infection</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>(<issue>6</issue>):<fpage>588</fpage>-<lpage>606</lpage>. No abstract available. PMID: 19892900</citation>
</ref>
<ref id="bibr10-0148607112452001">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jesuit</surname><given-names>C</given-names></name>
<name><surname>Dillon</surname><given-names>C</given-names></name>
<name><surname>Compher</surname><given-names>C</given-names></name>
<name><surname>Lenders</surname><given-names>CM</given-names></name>
</person-group>; <collab>American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors</collab>. <article-title>A.S.P.E.N. clinical guidelines: nutrition support of hospitalized pediatric patients with obesity</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>34</volume>(<issue>1</issue>):<fpage>13</fpage>-<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr11-0148607112452001">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jaksic</surname><given-names>T</given-names></name>
<name><surname>Hull</surname><given-names>MA</given-names></name>
<name><surname>Modi</surname><given-names>BP</given-names></name>
<name><surname>Ching</surname><given-names>YA</given-names></name>
<name><surname>George</surname><given-names>D</given-names></name>
<name><surname>Compher</surname><given-names>C</given-names></name>
</person-group>; <collab>American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors</collab>. <article-title>A.S.P.E.N. clinical guidelines: nutrition support of neonates supported with extracorporeal membrane oxygenation</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>34</volume>(<issue>3</issue>):<fpage>247</fpage>-<lpage>253</lpage>.</citation>
</ref>
<ref id="bibr12-0148607112452001">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brown</surname><given-names>RO</given-names></name>
<name><surname>Compher</surname><given-names>C</given-names></name>
</person-group>; <collab>American Society for Parenteral and Enteral Nutrition Board of Directors</collab>. <article-title>A.S.P.E.N. clinical guidelines: nutrition support in adult acute and chronic renal failure</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>34</volume>(<issue>4</issue>):<fpage>366</fpage>-<lpage>377</lpage>.</citation>
</ref>
<ref id="bibr13-0148607112452001">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mueller</surname><given-names>C</given-names></name>
<name><surname>Compher</surname><given-names>C</given-names></name>
<name><surname>Druyan</surname><given-names>ME</given-names></name>
</person-group>; <collab>American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors</collab>. <article-title>A.S.P.E.N. clinical guidelines: nutrition screening, assessment, and intervention in adults</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2011</year>;<volume>35</volume>(<issue>1</issue>):<fpage>16</fpage>-<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr14-0148607112452001">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arsenault</surname><given-names>D</given-names></name>
<name><surname>Brenn</surname><given-names>M</given-names></name>
<name><surname>Kim</surname><given-names>S</given-names></name>
<etal/>
</person-group>; <collab>American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors</collab>. <article-title>A.S.P.E.N. clinical guidelines: hyperglycemia and hypoglycemia in the neonate receiving parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2012</year>;<volume>36</volume>(<issue>1</issue>):<fpage>81</fpage>-<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr15-0148607112452001">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guyatt</surname><given-names>GH</given-names></name>
<name><surname>Oxman</surname><given-names>AD</given-names></name>
<name><surname>Akl</surname><given-names>EA</given-names></name>
<etal/>
</person-group>. <article-title>GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables</article-title>. <source>J Clin Epidemiol</source>. <year>2011</year>;<volume>64</volume>:<fpage>383</fpage>-<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr16-0148607112452001">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guyatt</surname><given-names>GH</given-names></name>
<name><surname>Oxman</surname><given-names>AD</given-names></name>
<name><surname>Kunz</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>GRADE guidelines: 2. Framing the question and deciding on important outcomes</article-title>. <source>J Clin Epidemiol</source>. <year>2011</year>;<volume>64</volume>:<fpage>395</fpage>-<lpage>400</lpage>.</citation>
</ref>
<ref id="bibr17-0148607112452001">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balshem</surname><given-names>H</given-names></name>
<name><surname>Helfand</surname><given-names>M</given-names></name>
<name><surname>Schunemann</surname><given-names>HJ</given-names></name>
<etal/>
</person-group>. <article-title>GRADE guidelines: 3. Rating the quality of evidence</article-title>. <source>J Clin Epidemiol</source>. <year>2011</year>;<volume>64</volume>:<fpage>401</fpage>-<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr18-0148607112452001">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Druyan</surname><given-names>ME</given-names></name>
<name><surname>Compher</surname><given-names>C</given-names></name>
<name><surname>Boullata</surname><given-names>JI</given-names></name>
<etal/>
</person-group>; <collab>American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors</collab>. <article-title>Clinical guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients: applying the GRADE system to development of A.S.P.E.N. Clinical Guidelines</article-title> <source>JPEN J Parenter Enteral Nutr</source>. <year>2012</year>;<volume>36</volume>(<issue>1</issue>):<fpage>77</fpage>-<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr19-0148607112452001">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krinsley</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients</article-title>. <source>Mayo Clin Proc</source>. <year>2003</year>;<volume>78</volume>:<fpage>1471</fpage>-<lpage>1478</lpage>.</citation>
</ref>
<ref id="bibr20-0148607112452001">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McAlister</surname><given-names>FA</given-names></name>
<name><surname>Majumdar</surname><given-names>SR</given-names></name>
<name><surname>Blitz</surname><given-names>S</given-names></name>
<name><surname>Rowe</surname><given-names>BH</given-names></name>
<name><surname>Romney</surname><given-names>J</given-names></name>
<name><surname>Marrie</surname><given-names>TJ</given-names></name>
</person-group>. <article-title>The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia</article-title>. <source>Diabetes Care</source>. <year>2005</year>;<volume>28</volume>:<fpage>810</fpage>-<lpage>815</lpage>.</citation>
</ref>
<ref id="bibr21-0148607112452001">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van den Berghe</surname><given-names>G</given-names></name>
<name><surname>Wouters</surname><given-names>P</given-names></name>
<name><surname>Weekers</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Intensive insulin therapy in critically ill patients</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>345</volume>:<fpage>1359</fpage>-<lpage>1367</lpage>.</citation>
</ref>
<ref id="bibr22-0148607112452001">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furnary</surname><given-names>AP</given-names></name>
<name><surname>Gao</surname><given-names>G</given-names></name>
<name><surname>Grunkemeier</surname><given-names>GL</given-names></name>
<etal/>
</person-group>. <article-title>Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2003</year>;<volume>125</volume>:<fpage>1007</fpage>-<lpage>1021</lpage>.</citation>
</ref>
<ref id="bibr23-0148607112452001">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krinsley</surname><given-names>JS</given-names></name>
</person-group>. <article-title>Effect of an intensive glucose management protocol on the mortality of critically ill adult patients</article-title>. <source>Mayo Clin Proc</source>. <year>2004</year>;<volume>79</volume>:<fpage>992</fpage>-<lpage>1000</lpage>.</citation>
</ref>
<ref id="bibr24-0148607112452001">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheung</surname><given-names>NW</given-names></name>
<name><surname>Napier</surname><given-names>B</given-names></name>
<name><surname>Zaccaria</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Hyperglycemia is associated with adverse outcomes in patients receiving total parenteral nutrition</article-title>. <source>Diabetes Care</source>. <year>2005</year>;<volume>28</volume>:<fpage>2367</fpage>-<lpage>2371</lpage>.</citation>
</ref>
<ref id="bibr25-0148607112452001">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van den Berghe</surname><given-names>G</given-names></name>
<name><surname>Wilmer</surname><given-names>A</given-names></name>
<name><surname>Hermans</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Intensive insulin therapy in the medical ICU</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>354</volume>(<issue>5</issue>):<fpage>449</fpage>-<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr26-0148607112452001">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname><given-names>LY</given-names></name>
<name><surname>Lin</surname><given-names>HC</given-names></name>
<name><surname>Lee</surname><given-names>PC</given-names></name>
<etal/>
</person-group>. <article-title>Hyperglycemia correlates with outcomes in patients receiving total parenteral nutrition</article-title>. <source>Am J Med Sci</source>. <year>2007</year>;<volume>333</volume>:<fpage>261</fpage>-<lpage>265</lpage>.</citation>
</ref>
<ref id="bibr27-0148607112452001">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brunkhorst</surname><given-names>FM</given-names></name>
<name><surname>Engel</surname><given-names>C</given-names></name>
<name><surname>Bloos</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Intensive insulin therapy and pentastarch resuscitation in severe sepsis</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>:<fpage>125</fpage>-<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr28-0148607112452001">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De</surname><given-names>La</given-names></name>
<name><surname>Rosa</surname><given-names>GDC</given-names></name>
<name><surname>Donado</surname><given-names>JH</given-names></name>
<name><surname>Restrepo</surname><given-names>AH</given-names></name>
<etal/>
</person-group>. <article-title>Strict glycaemic control in patients hospitalized in a mixed medical and surgical intensive care unit: a randomized clinical trial</article-title>. <source>Crit Care</source>. <year>2008</year>;<volume>12</volume>:<fpage>R120</fpage>.</citation>
</ref>
<ref id="bibr29-0148607112452001">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arabi</surname><given-names>YM</given-names></name>
<name><surname>Dabbagh</surname><given-names>OC</given-names></name>
<name><surname>Tamim</surname><given-names>HM</given-names></name>
<etal/>
</person-group>. <article-title>Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients</article-title>. <source>Crit Care Med</source>. <year>2008</year>;<volume>36</volume>:<fpage>3190</fpage>-<lpage>3197</lpage>.</citation>
</ref>
<ref id="bibr30-0148607112452001">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Preiser</surname><given-names>JC</given-names></name>
<name><surname>Devos</surname><given-names>P</given-names></name>
<name><surname>Ruiz-Santana</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>A prospective randomized multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study</article-title>. <source>Intensive Care Med</source>. <year>2009</year>;<volume>35</volume>:<fpage>1738</fpage>-<lpage>1748</lpage>.</citation>
</ref>
<ref id="bibr31-0148607112452001">
<label>31.</label>
<citation citation-type="journal">
<collab>NICE-SUGAR Study Investigators</collab>. <article-title>Intensive versus conventional glucose control in critically ill patients</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>:<fpage>1283</fpage>-<lpage>1297</lpage>.</citation>
</ref>
<ref id="bibr32-0148607112452001">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarkisian</surname><given-names>S</given-names></name>
<name><surname>Fenton</surname><given-names>TR</given-names></name>
<name><surname>Shaheen</surname><given-names>AA</given-names></name>
<name><surname>Raman</surname><given-names>M</given-names></name>
</person-group>. <article-title>Parenteral nutrition–associated hyperglycemia in non-critically ill patients associated with higher mortality</article-title>. <source>Can J Gastroenterol</source>. <year>2010</year>;<volume>24</volume>:<fpage>453</fpage>-<lpage>457</lpage>.</citation>
</ref>
<ref id="bibr33-0148607112452001">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>H</given-names></name>
<name><surname>Koh</surname><given-names>SO</given-names></name>
<name><surname>Park</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Higher destrose delivery via TPN related to development of hyperglycemia in non-diabetic critically ill patients</article-title>. <source>Nutr Research and Pract</source>. <year>2011</year>;<volume>5</volume>:<fpage>450</fpage>-<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr34-0148607112452001">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garber</surname><given-names>AJ</given-names></name>
<name><surname>Moghissi</surname><given-names>ES</given-names></name>
<name><surname>Bransome</surname><given-names>ED</given-names></name>
<etal/>
</person-group>. <article-title>ACE position statement</article-title>. <source>Endocrine Pract</source>. <year>2004</year>;<volume>10</volume>:<fpage>5</fpage>-<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr35-0148607112452001">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marik</surname><given-names>PE</given-names></name>
<name><surname>Preiser</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Toward understanding tight glycemic control in the ICU</article-title>. <source>Chest</source>. <year>2010</year>;<volume>137</volume>:<fpage>544</fpage>-<lpage>551</lpage>.</citation>
</ref>
<ref id="bibr36-0148607112452001">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moghissi</surname><given-names>ES</given-names></name>
<name><surname>Korytkowski</surname><given-names>MT</given-names></name>
<name><surname>DiNardo</surname><given-names>M</given-names></name>
<etal/>
</person-group>; <collab>American Association of Clinical Endocrinologists; American Diabetes Association</collab>. <article-title>American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control</article-title>. <source>Diabetes Care</source>. <year>2009</year>;<volume>32</volume>: <fpage>1119</fpage>-<lpage>1131</lpage>.</citation>
</ref>
<ref id="bibr37-0148607112452001">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Umpierrez</surname><given-names>GE</given-names></name>
<name><surname>Hellman</surname><given-names>R</given-names></name>
<name><surname>Korytkowski</surname><given-names>MT</given-names></name>
<etal/>
</person-group>. <article-title>Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2012</year>;<volume>97</volume>: <fpage>16</fpage>-<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr38-0148607112452001">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Egi</surname><given-names>M</given-names></name>
<name><surname>Bellomo</surname><given-names>R</given-names></name>
<name><surname>Stachowski</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Hypoglycemia and outcome in critically ill patients</article-title>. <source>Mayo Clin Proc</source>. <year>2010</year>;<volume>85</volume>:<fpage>217</fpage>-<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr39-0148607112452001">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cryer</surname><given-names>PE</given-names></name>
<name><surname>Davis</surname><given-names>SN</given-names></name>
<name><surname>Shamoon</surname><given-names>H</given-names></name>
</person-group>. <article-title>Hypoglycemia in diabetes</article-title>. <source>Diabetes Care</source>. <year>2003</year>;<volume>26</volume>:<fpage>1902</fpage>-<lpage>1912</lpage>.</citation>
</ref>
<ref id="bibr40-0148607112452001">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boucai</surname><given-names>L</given-names></name>
<name><surname>Southern</surname><given-names>WN</given-names></name>
<name><surname>Zonszein</surname><given-names>J</given-names></name>
</person-group>. <article-title>Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities</article-title>. <source>Am J Med</source>. <year>2011</year>;<volume>71</volume>:<fpage>1108</fpage>-<lpage>1114</lpage>.</citation>
</ref>
<ref id="bibr41-0148607112452001">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chi</surname><given-names>A</given-names></name>
<name><surname>Lissauer</surname><given-names>ME</given-names></name>
<name><surname>Kirchoffner</surname><given-names>J</given-names></name>
<name><surname>Scalea</surname><given-names>TM</given-names></name>
<name><surname>Johnson</surname><given-names>SB</given-names></name>
</person-group>. <article-title>Effect of glycemic state on hospital mortality in critically ill surgical patients</article-title>. <source>Am Surg</source>. <year>2011</year>;<volume>77</volume>(<issue>11</issue>):<fpage>1483</fpage>-<lpage>1489</lpage>.</citation>
</ref>
<ref id="bibr42-0148607112452001">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>D’Ancona</surname><given-names>G</given-names></name>
<name><surname>Bertuzzi</surname><given-names>F</given-names></name>
<name><surname>Sacchi</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Iatrogenic hypoglycemia secondary to tight glucose control is an independent determinant for mortality and cardiac morbidity</article-title>. <source>Eur J Cardiothorac Surg</source>. <year>2011</year>;<volume>40</volume>:<fpage>360</fpage>-<lpage>366</lpage>.</citation>
</ref>
<ref id="bibr43-0148607112452001">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hermanides</surname><given-names>J</given-names></name>
<name><surname>Bosman</surname><given-names>RJ</given-names></name>
<name><surname>Vriesendorp</surname><given-names>TM</given-names></name>
<etal/>
</person-group>. <article-title>Hypoglycemia is associated with intensive care unit mortality</article-title>. <source>Crit Care Med</source>. <year>2010</year>;<volume>38</volume>: <fpage>1430</fpage>-<lpage>1434</lpage>.</citation>
</ref>
<ref id="bibr44-0148607112452001">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krinsley</surname><given-names>JS</given-names></name>
<name><surname>Schultz</surname><given-names>MJ</given-names></name>
<name><surname>Spronk</surname><given-names>PE</given-names></name>
<etal/>
</person-group>. <article-title>Mild hypoglycemia is independently associated with increased mortality in the critically ill</article-title>. <source>Crit Care</source>. <year>2011</year>;<volume>15</volume>(<issue>4</issue>):<fpage>R173</fpage>.</citation>
</ref>
<ref id="bibr45-0148607112452001">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mortensen</surname><given-names>EM</given-names></name>
<name><surname>Garcia</surname><given-names>S</given-names></name>
<name><surname>Leykum</surname><given-names>L</given-names></name>
<name><surname>Nakashima</surname><given-names>B</given-names></name>
<name><surname>Restrepo</surname><given-names>MI</given-names></name>
<name><surname>Anzueto</surname><given-names>A</given-names></name>
</person-group>. <article-title>Association of hypoglycemia with mortality for subjects hospitalized with pneumonia</article-title>. <source>Am J Med Sci</source>. <year>2010</year>;<volume>339</volume>:<fpage>239</fpage>-<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr46-0148607112452001">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Siegelaar</surname><given-names>SE</given-names></name>
<name><surname>Hermanides</surname><given-names>J</given-names></name>
<name><surname>Oudemans-van Straaten</surname><given-names>HM</given-names></name>
<etal/>
</person-group>. <article-title>Mean glucose during ICU admission is related to mortality by a U-shaped curve in surgical and medical patients: a retrospective cohort study</article-title>. <source>Crit Care</source>. <year>2010</year>;<volume>14</volume>:<fpage>R224</fpage>.</citation>
</ref>
<ref id="bibr47-0148607112452001">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stamou</surname><given-names>SC</given-names></name>
<name><surname>Nussbaum</surname><given-names>M</given-names></name>
<name><surname>Carew</surname><given-names>JD</given-names></name>
<etal/>
</person-group>. <article-title>Hypoglycemia with intensive insulin therapy after cardiac surgery: predisposing factors and association with mortality</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2011</year>;<volume>142</volume>:<fpage>166</fpage>-<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr48-0148607112452001">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Durao</surname><given-names>MS</given-names></name>
<name><surname>Marra</surname><given-names>AR</given-names></name>
<name><surname>Moura</surname><given-names>DF</given-names></name>
<etal/>
</person-group>. <article-title>Tight glucose control versus intermediate glucose control: a quasi-experimental study</article-title>. <source>Anaesth Intensive Care</source>. <year>2010</year>;<volume>38</volume>(<issue>3</issue>):<fpage>467</fpage>-<lpage>473</lpage>.</citation>
</ref>
<ref id="bibr49-0148607112452001">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arabi</surname><given-names>YM</given-names></name>
<name><surname>Tamim</surname><given-names>HM</given-names></name>
<name><surname>Rishu</surname><given-names>AH</given-names></name>
</person-group>. <article-title>Hypoglycemia with intensive insulin therapy in critically ill patients: predisposing factors and association with mortality</article-title>. <source>Crit Care Med</source>. <year>2009</year>;<volume>37</volume>(<issue>9</issue>):<fpage>2536</fpage>-<lpage>2544</lpage>.</citation>
</ref>
<ref id="bibr50-0148607112452001">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kosiborod</surname><given-names>M</given-names></name>
<name><surname>Inzucchi</surname><given-names>SE</given-names></name>
<name><surname>Goyal</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction</article-title>. <source>JAMA</source>. <year>2009</year>;<volume>301</volume>(<issue>15</issue>):<fpage>1556</fpage>-<lpage>1564</lpage>.</citation>
</ref>
<ref id="bibr51-0148607112452001">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Turchin</surname><given-names>A</given-names></name>
<name><surname>Matheny</surname><given-names>ME</given-names></name>
<name><surname>Shubina</surname><given-names>M</given-names></name>
<name><surname>Scanlon</surname><given-names>JV</given-names></name>
<name><surname>Greenwood</surname><given-names>B</given-names></name>
<name><surname>Pendergrass</surname><given-names>ML</given-names></name>
</person-group>. <article-title>Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward</article-title>. <source>Diabetes Care</source>. <year>2009</year>;<volume>32</volume>(<issue>7</issue>):<fpage>1153</fpage>-<lpage>1157</lpage>.</citation>
</ref>
<ref id="bibr52-0148607112452001">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bagshaw</surname><given-names>SM</given-names></name>
<name><surname>Bellomo</surname><given-names>R</given-names></name>
<name><surname>Jacka</surname><given-names>MJ</given-names></name>
<name><surname>Egi</surname><given-names>M</given-names></name>
<name><surname>Hart</surname><given-names>GK</given-names></name>
<name><surname>George</surname><given-names>C</given-names></name>
</person-group>; <collab>ANZICS CORE Management Committee</collab>. <article-title>The impact of early hypoglycemia and blood glucose variability on outcome in critical illness</article-title>. <source>Crit Care</source>. <year>2009</year>;<volume>13</volume>(<issue>3</issue>):<fpage>R91</fpage>.</citation>
</ref>
<ref id="bibr53-0148607112452001">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaukonen</surname><given-names>KM</given-names></name>
<name><surname>Rantala</surname><given-names>M</given-names></name>
<name><surname>Pettilä</surname><given-names>V</given-names></name>
<name><surname>Hynninen</surname><given-names>M</given-names></name>
</person-group>. <article-title>Severe hypoglycemia during intensive insulin therapy</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>2009</year>;<volume>53</volume>(<issue>1</issue>):<fpage>61</fpage>-<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr54-0148607112452001">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krinsley</surname><given-names>JS</given-names></name>
<name><surname>Grover</surname><given-names>A</given-names></name>
</person-group>. <article-title>Severe hypoglycemia in critically ill patients: risk factors and outcomes</article-title>. <source>Crit Care Med</source>. <year>2007</year>;<volume>35</volume>(<issue>10</issue>):<fpage>2262</fpage>-<lpage>2267</lpage>.</citation>
</ref>
<ref id="bibr55-0148607112452001">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cryer</surname><given-names>PE</given-names></name>
</person-group>. <article-title>Mechanisms of hypoglycemia-associated autonomic failure and the component syndromes in diabetes</article-title>. <source>Diabetes</source>. <year>2005</year>;<volume>54</volume>:<fpage>3592</fpage>-<lpage>3601</lpage>.</citation>
</ref>
<ref id="bibr56-0148607112452001">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>SN</given-names></name>
<name><surname>Shavers</surname><given-names>C</given-names></name>
<name><surname>Mosqueda-Garcia</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans</article-title>. <source>Diabetes</source>. <year>1997</year>;<volume>46</volume>:<fpage>1328</fpage>-<lpage>1335</lpage>.</citation>
</ref>
<ref id="bibr57-0148607112452001">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adler</surname><given-names>GK</given-names></name>
<name><surname>Bonyhay</surname><given-names>I</given-names></name>
<name><surname>Failing</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemia control</article-title>. <source>Diabetes</source>. <year>2009</year>;<volume>58</volume>:<fpage>360</fpage>-<lpage>366</lpage>.</citation>
</ref>
<ref id="bibr58-0148607112452001">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kanji</surname><given-names>S</given-names></name>
<name><surname>Buffie</surname><given-names>J</given-names></name>
<name><surname>Hutton</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Reliability of point-of-care testing for glucose measurement in critically ill adults</article-title>. <source>Crit Care Med</source>. <year>2005</year>;<volume>33</volume>: <fpage>2778</fpage>-<lpage>2785</lpage>.</citation>
</ref>
<ref id="bibr59-0148607112452001">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leon-Sanz</surname><given-names>M</given-names></name>
<name><surname>Garcia-Luna</surname><given-names>PP</given-names></name>
<name><surname>Sanz-Paris</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Glycemic and lipid control in hospitalized type 2 diabetic patients: evaluation of 2 enteral nutrition formulas (low carbohydrate–high monounsaturated fat vs high carbohydrate)</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2005</year>;<volume>29</volume>(<issue>1</issue>):<fpage>21</fpage>-<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr60-0148607112452001">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mesejo</surname><given-names>A</given-names></name>
<name><surname>Acosta</surname><given-names>JA</given-names></name>
<name><surname>Ortega</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of a high-protein disease-specific enteral formula with a high-protein enteral formula in hyperglycemic critically ill patients</article-title>. <source>Clin Nutr</source>. <year>2003</year>;<volume>22</volume>(<issue>3</issue>):<fpage>295</fpage>-<lpage>305</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>